Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Lineage Cell Therapeutics (LCTX) Leases (2016 - 2025)

Historic Leases for Lineage Cell Therapeutics (LCTX) over the last 10 years, with Q3 2025 value amounting to $2.3 million.

  • Lineage Cell Therapeutics' Leases fell 215.92% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 215.92%. This contributed to the annual value of $2.1 million for FY2024, which is 1498.81% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Leases of $2.3 million as of Q3 2025, which was down 215.92% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Leases registered a high of $3.5 million during Q4 2022, and its lowest value of $28000.0 during Q1 2022.
  • In the last 5 years, Lineage Cell Therapeutics' Leases had a median value of $2.5 million in 2022 and averaged $2.4 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Leases crashed by 9894.26% in 2022, and later surged by 1138214.29% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Leases (Quarter) stood at $2.4 million in 2021, then soared by 48.27% to $3.5 million in 2022, then decreased by 28.29% to $2.5 million in 2023, then decreased by 14.99% to $2.1 million in 2024, then grew by 7.79% to $2.3 million in 2025.
  • Its Leases was $2.3 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.9 million in Q1 2025.